Patents by Inventor Masazumi Matsumura

Masazumi Matsumura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FORMULATIONS
    Publication number: 20190345238
    Abstract: The invention provides a formulation comprising a buffer with a pH from about 4.0 to about 6.0, proline and an effective amount of a polypeptide. The polypeptide can be an antibody. The specification also provides methods of preparing the formulation, a kit containing the formulation and methods of using the formulation.
    Type: Application
    Filed: May 22, 2019
    Publication date: November 14, 2019
    Applicant: AMGEN INC.
    Inventors: Jaby JACOB, Masazumi MATSUMURA, Yatin GOKARN, David BREMS
  • FORMULATIONS
    Publication number: 20150315271
    Abstract: The invention provides a formulation comprising a buffer with a pH from about 4.0 to about 6.0, proline and an effective amount of a polypeptide. The polypeptide can be an antibody. The specification also provides methods of preparing the formulation, a kit containing the formulation and methods of using the formulation.
    Type: Application
    Filed: May 5, 2015
    Publication date: November 5, 2015
    Applicant: AMGEN INC.
    Inventors: Jaby JACOB, Masazumi MATSUMURA, Yatin GOKARN, David BREMS
  • Stable polypeptide formulations
    Patent number: 8241632
    Abstract: The invention provides a formulation including a buffer having a pH less than 6.0, a divalent cation between about 5-200 mM, an excipient comprising a sugar or polyol and an effective amount of a therapeutic polypeptide. Also provided is a method of stabilizing a polypeptide. The method includes contacting a therapeutic polypeptide with a concentration of divalent cation between about 5-150 150 mM in a buffer having a pH less than 6.0 and an excipient comprising a sugar or polyol.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: August 14, 2012
    Assignee: Amgen Inc.
    Inventors: Douglas Rehder, Pavel Bondarenko, Dirk Chelius, Arnold McAuley, Masazumi Matsumura
  • Stable Polypeptide Formulations
    Publication number: 20100158908
    Abstract: The invention provides a formulation including a buffer having a pH less than 6.0, a divalent cation between about 5-200 mM, an excipient comprising a sugar or polyol and an effective amount of a therapeutic polypeptide. Also provided is a method of stabilizing a polypeptide. The method includes contacting a therapeutic polypeptide with a concentration of divalent cation between about 5-150 150 mM in a buffer having a pH less than 6.0 and an excipient comprising a sugar or polyol.
    Type: Application
    Filed: March 5, 2010
    Publication date: June 24, 2010
    Inventors: Douglas Rehder, Pavel Bondarenko, Dirk Chelius, Arnold Mcauley, Masazumi Matsumura
  • Stable polypeptide formulations
    Patent number: 7705132
    Abstract: The invention provides a formulation including a buffer having a pH less than 6.0, a divalent cation between about 5-200 mM, an excipient comprising a sugar or polyol and an effective amount of a therapeutic polypeptide. Also provided is a method of stabilizing a polypeptide. The method includes contacting a therapeutic polypeptide with a concentration of divalent cation between about 5-150 150 mM in a buffer having a pH less than 6.0 and an excipient comprising a sugar or polyol.
    Type: Grant
    Filed: October 5, 2007
    Date of Patent: April 27, 2010
    Assignee: Amgen Inc.
    Inventors: Douglas Rehder, Pavel Bondarenko, Dirk Chelius, Arnold McAuley, Masazumi Matsumura
  • Formulations That Inhibit Protein Aggregation
    Publication number: 20100056765
    Abstract: Disclosed is a stable pharmaceutically acceptable formulation containing a pharmaceutically acceptable amount of a protein. Also disclosed are methods for preparing such formulations and methods for inhibiting protein aggregate formation induced by physical stresses associated with processing, manufacture, shipping, and storing protein formulations, particularly freeze/thaw stress.
    Type: Application
    Filed: August 25, 2009
    Publication date: March 4, 2010
    Applicant: AMGEN INC.
    Inventors: Stephen R. Brych, Masazumi Matsumura
  • Formulations
    Publication number: 20080213282
    Abstract: The invention provides a formulation comprising a buffer with a pH from about 4.0 to about 6.0, proline and an effective amount of a polypeptide. The polypeptide can be an antibody. The specification also provides methods of preparing the formulation, a kit containing the formulation and methods of using the formulation.
    Type: Application
    Filed: December 19, 2007
    Publication date: September 4, 2008
    Inventors: Jaby Jacob, Masazumi Matsumura, Yatin Gokarn, David Brems
  • Stable polypeptide formulations
    Publication number: 20080124326
    Abstract: The invention provides a formulation including a buffer having a pH less than 6.0, a divalent cation between about 5-200 mM, an excipient comprising a sugar or polyol and an effective amount of a therapeutic polypeptide. Also provided is a method of stabilizing a polypeptide. The method includes contacting a therapeutic polypeptide with a concentration of divalent cation between about 5-150 150 mM in a buffer having a pH less than 6.0 and an excipient comprising a sugar or polyol.
    Type: Application
    Filed: October 5, 2007
    Publication date: May 29, 2008
    Applicant: Amgen Inc.
    Inventors: Douglas Rehder, Pavel Bondarenko, Dirk Chelius, Arnold McAuley, Masazumi Matsumura
  • Stable formulations
    Publication number: 20080112953
    Abstract: The invention provides a formulation including an acetic acid buffer, a glutamic acid buffer or a succinic acid buffer with a pH from about 4.5-7.0, at least one excipient comprising a sugar or a polyol and an effective amount of a therapeutic antibody. The buffer can include a salt of acetate, glutamate or succinate and the sugar or polyol can include glycerol, sucrose, trehalose or sorbitol. The therapeutic antibody can include a human antibody, a humanized antibody, a chimeric antibody, or a functional fragment thereof.
    Type: Application
    Filed: October 5, 2007
    Publication date: May 15, 2008
    Applicant: Amgen Inc.
    Inventors: Arnold McAuley, Douglas Rehder, Masazumi Matsumura
  • FORMULATIONS THAT INHIBIT PROTEIN AGGREGATION
    Publication number: 20070190047
    Abstract: Disclosed is a stable pharmaceutically acceptable formulation containing a pharmaceutically acceptable amount of a protein. Also disclosed are methods for preparing such formulations and methods for inhibiting protein aggregate formation induced by physical stresses associated with processing, manufacture, shipping, and storing protein formulations, particularly freeze/thaw stress.
    Type: Application
    Filed: July 31, 2006
    Publication date: August 16, 2007
    Inventors: Stephen Brych, Masazumi Matsumura